Cessatech reports first patient dosed in final Safety Study 0202 of lead product candidate CT001
· First patient has been dosed in Safety Study 0202 of lead candidate CT001. · The Safety Study 0202 is an open-label, prospective study to assess safety, tolerability, analgesic effect, and feasibility of CT001 in 150 paediatric patients with moderate to severe pain, in the emergency setting. · Cessatech expects the study to be completed by the end of 2024.27 May - Cessatech A/S announces that the Safety Study 0202 has now been initiated with dosing of the first patient. The trial will assess safety, tolerability, analgesic effect, and feasibility of CT001 in 150 paediatric patients